Achillion Pharma Appoints Steven Zelenkofske Chief Medical Officer

Steven Zelenkofske has joined Achillion Pharmaceuticals (NASDAQ: [[ticker:ACHN]]) as executive vice president and chief medical officer of the New Haven, CT, drug developer. Zelenkofske most recently worked at uniQure (NASDAQ: [[ticker:QURE]]), where he was chief medical officer. He has also held leadership positions at Regado Biosciences, AstraZeneca (NYSE: [[ticker:AZN]]), Sanofi-Aventis, Boston Scientific (NYSE: [[ticker:BSX]]), and Novartis (NYSE: [[ticker:NVS]]). Achillion develops drugs to treat rare immune disorders.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan